search
Back to results

Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial (SMART_MS)

Primary Purpose

Multiple Sclerosis

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
SMART
Sham brain training (Sudoku)
Sponsored by
University of Lincoln
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Sclerosis

Eligibility Criteria

18 Years - 89 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of MS, received ≥3-months pre-enrolment (allowing for acute adjustment, as per other trials of cognitive rehabilitation)
  • Age 18-89 (to meet the standardisation criteria of psychometric assessments)
  • Cognitive difficulties as assessed by Perceived Deficits Questionnaire (PDQ) self-report (≥27) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) testing (≤1 standard deviation below normative reference-value)
  • Able to read and speak English to standard necessary for completing assessment and intervention procedures
  • Able and willing to access a computer/tablet/smart-phone with internet connection throughout the study
  • Able and willing to give informed consent

Exclusion Criteria:

  • Currently receiving cognitive rehabilitation
  • Previously received SMART training
  • Vision or hearing problems precluding completion of procedures

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Sham Comparator

    No Intervention

    Arm Label

    TAU + SMART

    TAU + Sham training

    TAU (treatment-as-usual)

    Arm Description

    Participants in this arm will receive treatment-as-usual (TAU) plus the experimental SMART intervention (theory-based cognitive training)

    Participants in this arm will receive treatment-as-usual (TAU) plus a control (sham) cognitive training intervention

    Participants in this arm will receive treatment-as-usual (TAU). Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites.

    Outcomes

    Primary Outcome Measures

    Recruitment and retention rates
    Numbers eligible/interested/consented and randomised (and reasons for non-participation), number completing baseline and outcome assessments at Follow-up 1
    Completion rates of outcome measures
    Missing response-data
    Intervention drop-out rate
    Numbers in the intervention condition that drop out (complete <6 sessions) and reasons for intervention non-completion

    Secondary Outcome Measures

    Full Information

    First Posted
    July 1, 2021
    Last Updated
    July 14, 2021
    Sponsor
    University of Lincoln
    Collaborators
    University of Exeter, Nottinghamshire Healthcare NHS Trust, National University of Ireland, Maynooth, University of Nottingham
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04975685
    Brief Title
    Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial
    Acronym
    SMART_MS
    Official Title
    Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 1, 2021 (Anticipated)
    Primary Completion Date
    April 30, 2023 (Anticipated)
    Study Completion Date
    April 30, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Lincoln
    Collaborators
    University of Exeter, Nottinghamshire Healthcare NHS Trust, National University of Ireland, Maynooth, University of Nottingham

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Background: Multiple Sclerosis (MS) is a chronic condition of the central nervous system; around 1 in 600 people in the United Kingdom have MS. Many people with MS (70%) have cognitive difficulties, which they experience as distressing and disabling, and there is currently a lack of treatment options to improve these difficulties. SMART (Strengthening Mental Abilities with Relational Training) - a theory-based online cognitive training programme, which has been shown to improve general cognitive abilities - has not been tested with people who have MS. Aims: To conduct a feasibility study to inform development of a definitive trial of SMART for improving cognitive functioning in people with MS. The investigators will assess: Acceptability to participants of the intervention, delivery format, inclusion/exclusion criteria, baseline and outcome measures, randomisation protocol, and study procedures The framework for a cost-effectiveness analysis alongside a definitive trial Participant recruitment and retention rates Sample-size needed for fully powered trial Signal of efficacy Plan: To address Aims 1-5, the investigators will recruit 60 adults with MS who are experiencing cognitive difficulties, identified from MS clinics. Participants will complete baseline assessments of their cognitive abilities and answer questionnaires about their cognitive difficulties, personal priorities, mood, fatigue, self-efficacy, quality of life, and healthcare services used. Assessments will be administered by a researcher, face-to-face or remotely. Participants will be randomly allocated to one of three arms (20 per group): Group 1: Receives SMART intervention online - plus usual care (MS Nurse support). SMART intervention involves completing a series of logic problems, which are designed to train skills that scaffold complex cognition. Group 2: Receives usual care alone. Group 3: Receives a 'control' intervention online - plus usual care. Baseline measures will be re-administered at three- and six-months post-randomisation. Researchers and patient-partners (people with personal experience of MS, who will act as co-researchers) will also interview 30 participants about their experience of the study and treatment. All qualitative data will be transcribed and thematically analysed in terms of a priori feasibility aims. Quantitative data will enable sample-size calculation for a definitive study and determine signal of efficacy.
    Detailed Description
    Background: Cognitive deficits have been identified as the most debilitating impact of MS. These deficits interfere with daily living, manifesting as inattention (e.g., getting easily distracted), forgetting (e.g., leaving the stove on after cooking), and problem-solving difficulties (e.g., getting confused when completing a multi-stage task like cooking). The burden of these deficits reduces quality of life and restricts daily activities and employment - and correspondingly, diminishes patient perceptions of personal competence and self-worth. Cognitive rehabilitation is not routinely offered in the National Health Service (NHS) - and, when it is offered, largely focuses on teaching people to compensate for deficits (e.g., using external memory aids) rather than retraining cognitive skills. A recent state-of-the-field review from international MS experts has called for research towards identifying effective, evidence-based, and clinically feasible interventions to address cognitive deficits in MS. There is evident uncertainty about how to intervene effectively, and this is recognised by the James Lind Alliance as a top-10 priority area for research-funding. Our trial tests the feasibility of a highly accessible and low-resource format of cognitive rehabilitation (online training). Given NHS resource constraints, the scale of the problem, and concerns about face-to-face consultation in the context of COVID-19, new and cost-effective ways of implementing promising cognitive rehabilitation interventions are needed. Low-resource online formats are more likely to be implemented if found to be clinically effective, enable wider access for patients, and provide active support for self-management - consistent with (1) models of care for managing longer-term conditions and (2) the digital healthcare agenda. As a feasibility trial, outcomes are unlikely to immediately effect changes to NHS practice. However, this is a necessary step towards developing a definitive trial - and will give us a signal of efficacy, a prerequisite for progression to a definitive trial. If found to be clinically- and cost-effective, the latter trial could create a step-change in MS cognitive rehabilitation - improving service-delivery and optimising support with limited additional resources. Aim: To conduct a feasibility study to inform development of a definitive trial of SMART (an online 'brain training' treatment) for improving cognitive functioning in people with MS. The investigators will assess: Acceptability to participants of the intervention, delivery format, inclusion/exclusion criteria, baseline and outcome measures, randomisation protocol, and study procedures The framework for a cost-effectiveness analysis alongside a definitive trial Participant recruitment and retention rates Sample-size needed for fully powered trial Signal of efficacy Research plan: The investigators will conduct a three-arm feasibility Randomised Controlled Trial (RCT) comparing (1) SMART + treatment-as-usual (TAU) with (2) TAU and (3) active control ('sham') training + TAU. Consenting eligible patients will complete a baseline cognitive assessment battery and questionnaires assessing impact of living with MS, health-related quality of life, subjective cognitive difficulties, and service/resource-use. After completing baseline assessments, participants will be randomly allocated to one of three arms (using minimisation to balance participant characteristics across arms): SMART + TAU TAU. Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites. Sham training (active control: Sudoku) + TAU. The investigators selected Sudoku to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials. Sham-training will be delivered online, over the same timeframe/regimen as SMART treatment, and with telephone support to facilitate access - controlling for modality, schedule of engagement, and relational support. A Research Fellow will complete blinded outcomes at 3- and 6-months post-randomisation, by re-administering baseline measures. Quantitative data will enable sample-size calculation for a definitive study and determine signal of efficacy. After the first follow-up assessment (>3 months post-randomisation) a sub-sample of participants will engage in feasibility-feedback interviews.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Multiple Sclerosis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Outcomes Assessor
    Allocation
    Randomized
    Enrollment
    60 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    TAU + SMART
    Arm Type
    Experimental
    Arm Description
    Participants in this arm will receive treatment-as-usual (TAU) plus the experimental SMART intervention (theory-based cognitive training)
    Arm Title
    TAU + Sham training
    Arm Type
    Sham Comparator
    Arm Description
    Participants in this arm will receive treatment-as-usual (TAU) plus a control (sham) cognitive training intervention
    Arm Title
    TAU (treatment-as-usual)
    Arm Type
    No Intervention
    Arm Description
    Participants in this arm will receive treatment-as-usual (TAU). Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites.
    Intervention Type
    Behavioral
    Intervention Name(s)
    SMART
    Intervention Description
    SMART (Strengthening Mental Abilities Through Relational Training) is a web-based cognitive training program that directly trains 'relational skills' - skills necessary to understand how concepts relate to one another, which underpin complex cognition.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Sham brain training (Sudoku)
    Intervention Description
    Sudoku was selected to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials.
    Primary Outcome Measure Information:
    Title
    Recruitment and retention rates
    Description
    Numbers eligible/interested/consented and randomised (and reasons for non-participation), number completing baseline and outcome assessments at Follow-up 1
    Time Frame
    16 months
    Title
    Completion rates of outcome measures
    Description
    Missing response-data
    Time Frame
    6 months
    Title
    Intervention drop-out rate
    Description
    Numbers in the intervention condition that drop out (complete <6 sessions) and reasons for intervention non-completion
    Time Frame
    3 months
    Other Pre-specified Outcome Measures:
    Title
    Perceived Deficits Questionnaire (PDQ)
    Description
    Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
    Time Frame
    Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
    Title
    Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
    Description
    Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
    Time Frame
    Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
    Title
    Symbol Digit Modalities Test (SDMT)
    Description
    Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
    Time Frame
    Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
    Title
    Generalized Anxiety Disorder Scale-7 (GAD-7)
    Description
    Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
    Time Frame
    Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
    Title
    Patient Health Questionnaire-9 (PHQ-9)
    Description
    Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
    Time Frame
    Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
    Title
    Modified Fatigue Impact Scale-5-Item (MFIS-5)
    Description
    Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
    Time Frame
    Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
    Title
    Personal Questionnaire (PQ)
    Description
    Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
    Time Frame
    Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
    Title
    EQ-5D-5L
    Description
    Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
    Time Frame
    Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
    Title
    MS Impact Scale-29 (MSIS-29)
    Description
    Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
    Time Frame
    Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
    Title
    ICECAP-A
    Description
    Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
    Time Frame
    Change between baseline and 3-month follow-up. Additional follow-up at 6 months.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    89 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Diagnosis of MS, received ≥3-months pre-enrolment (allowing for acute adjustment, as per other trials of cognitive rehabilitation) Age 18-89 (to meet the standardisation criteria of psychometric assessments) Cognitive difficulties as assessed by Perceived Deficits Questionnaire (PDQ) self-report (≥27) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) testing (≤1 standard deviation below normative reference-value) Able to read and speak English to standard necessary for completing assessment and intervention procedures Able and willing to access a computer/tablet/smart-phone with internet connection throughout the study Able and willing to give informed consent Exclusion Criteria: Currently receiving cognitive rehabilitation Previously received SMART training Vision or hearing problems precluding completion of procedures

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    36056385
    Citation
    Golijani-Moghaddam N, Dawson DL, Evangelou N, Turton J, Hawton A, Law GR, Roche B, Rowan E, Burge R, Frost AC, das Nair R. Strengthening Mental Abilities with Relational Training (SMART) in multiple sclerosis (MS): study protocol for a feasibility randomised controlled trial. Pilot Feasibility Stud. 2022 Sep 3;8(1):195. doi: 10.1186/s40814-022-01152-7.
    Results Reference
    derived

    Learn more about this trial

    Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial

    We'll reach out to this number within 24 hrs